Autopsy report · NCT01519323

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

“Study was terminated due to low enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year before it started.
• Ran for about 2 years 11 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

Malignant Melanoma

Interventions

vemurafenib

Participants

6

Sites

26

Countries

Australia, France, Germany, Israel, Italy, Poland, Slovakia, Spain, United Kingdom, United States

Trials that died the same way

• Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
  “Study terminated due to low enrollment.” (98% match in meaning)
• A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
  “The study was terminated due to low enrollment.” (98% match in meaning)
• Use of Teriparatide to Accelerate Fracture Healing
  “The study was terminated due to poor enrollment.” (96% match in meaning)
• A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
  “Study was terminated due to poor enrollment” (95% match in meaning)
• MIRACLE EF Clinical Study
  “The study was terminated early due to low enrollment.” (95% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.